NBIX Neurocrine: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

Contract manufacturing diversification provides Neurocrine Biosciences (NBIX) with high margins and stable supplies. This strengthens physician confidence in the brand, which develops breakthrough neurological drugs. Historical EPS YoY TTM dynamics clearly confirm this trend, where 62.00 represents the current level of the metric. The company's operations are supplemented by standard eco-initiatives focused on safe chemical disposal and energy efficiency.
NBIX (Neurocrine Biosciences, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the annual change in net income per share on a rolling year basis, reflecting the actual efficiency of capital generation. For Neurocrine Biosciences (NBIX), this parameter confirms the monetization of its patent portfolio and the success of key drugs in neurology therapy. By analyzing the EPS dynamics on a trailing twelve-month (TTM) basis, an investor determines the sustainability of cash flows. Stable growth of this metric minimizes the risk of profit shortfalls and justifies the long-term value of the asset.